3-11 Bellerose Drive
129 articles with Eagle Pharmaceuticals
Eagle Pharmaceuticals, Inc. announced today that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at the Morgan Stanley 16th Annual Global Healthcare Conference
Eagle Pharmaceuticals Concludes Enrollment of Second Safety and Efficacy Study at Hajj to Evaluate RYANODEX for Exertional Heat Stroke
Preliminary Analysis: RYANODEX Provides Benefit for Patients
Achieves #1 ranking for both 3-year EPS and revenue growth
BENDEKA protected by 16 patents running from 2026 through 2033
Q2 2018 net income was $0.18 per basic and $0.17 per diluted share and adjusted non-GAAP net income of $0.99 per basic and $0.95 per diluted share
Eagle Pharmaceuticals, Inc. announced that the Company will release its 2018 second quarter financial results on Tuesday, August 7, 2018, before the market opens.
FDA Grants Eagle Seven Year Orphan Drug Exclusivity for BENDEKA (bendamustine hydrochloride injection)
Eagle Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted seven years of orphan drug exclusivity (ODE) in the U.S., for BENDEKA™ (bendamustine hydrochloride injection, or bendamustine HCI)
Eagle Pharmaceuticals, Inc. today announced that an additional patent has been issued related to BENDEKA® by the United States Patent and Trademark Office (USPTO).
Court Issues Decision in Favor of Eagle Pharmaceuticals Granting Seven Year Orphan Drug Exclusivity for BENDEKA (bendamustine hydrochloride injection)
Generic TREANDA entry now not expected until December 2022
Eagle Pharmaceuticals, Inc. announced today that management will present at two investor conferences in June 2018.
Eagle Pharmaceuticals, Inc. Granted Final FDA Approval for Bendamustine Hydrochloride Ready-to-Dilute Solution in a 500ml Admixture
Eagle to ship 500ml admixture product immediately
Eagle Pharmaceuticals, Inc. announced that the Company will release its 2018 first quarter financial results on Thursday, May 10, 2018, before the market opens.
Eagle Pharmaceuticals, Inc. announced that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at the 43rd Annual Deutsche Bank Health Care Conferenc
Product is the generic version of Endo International plc’s original Vasostrict® formulation
The patent is directed to a technology that allows for the formulation of antibodies at high concentration.
Record 2017 revenue of $237 million
Eagle Pharmaceuticals, Inc. to Discuss Fourth Quarter and Year End 2017 Financial Results on February 26, 2018
A replay of the conference call will be available for one week after the call's completion by dialing 800-677-7320 (US) or 402-220-0666 (International) and entering conference call ID EGRXQ417.
The Company anticipates dosing its last subject during the first half of 2018, with study completion within twelve months, and an expected NDA filing in the fourth quarter of 2018.
Total revenue for the third quarter of 2017 grew 67% to $63.0 million compared to $37.8 million in the third quarter of 2016.
Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will host a conference call to discuss the results.